Sutro Biopharma, Inc.’s STRO share price has dipped by 8.30%, which has investors questioning if this is right time to buy.

Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 20 ...

FINANCIAL RESULTS "Wheaton delivered a strong start to 2025, with our core assets exceeding production expectations and driving record quarterly revenue, adjusted net earnings, and operating cash flow ...